Indication
Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Medicine details
- Medicine name:
- risankizumab (Skyrizi)
- SMC ID:
- SMC2686
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Publication due date:
- 13 January 2025